Mimi L. Quan

2.0k citations

48 papers · 1.4k indexed · h-index 22

Organic Chemistry top 5%
Hematology top 2%
Cardiology and Cardiovascular Medicine top 5%
Genetics top 2%
Molecular Biology

Co-authors: Ruth R. Wexler Donald J. Cram Pancras C. Wong Robert M. Knabb Joseph M. Luettgen Dietmar Seiffert Patrick Y. S. Lam Christopher D. Ellis
Topics: Blood Coagulation and Thrombosis Mechanisms (27 papers)Coagulation, Bradykinin, Polyphosphates, and Angioedema (21 papers)Atrial Fibrillation Management and Outcomes (9 papers)
Cited by: Hematology Internal Medicine Genetics
Journals: Journal of the American Chemical Society Circulation Blood
Partner nations: United States Germany Sweden

In The Last Decade

Mimi L. Quan

47 papers receiving 1.4k citations

Peers

Countries citing papers authored by Mimi L. Quan

Since Specialization

Citations

This map shows the geographic impact of Mimi L. Quan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mimi L. Quan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mimi L. Quan more than expected).

Fields of papers citing papers by Mimi L. Quan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mimi L. Quan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mimi L. Quan. The network helps show where Mimi L. Quan may publish in the future.

Co-authorship network of co-authors of Mimi L. Quan

This figure shows the co-authorship network connecting the top 25 collaborators of Mimi L. Quan. A scholar is included among the top collaborators of Mimi L. Quan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mimi L. Quan. Mimi L. Quan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantitative characterization of cellular morphology of turbulent hydrogen-air spherically expanding flames 2025 ·International Journal of Hydrogen Energy ·Haoran Zhao,(unknown),(unknown),Mimi L. Quan,Fuchao Tian,Chunmiao Yuan,(unknown)	1
2	Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors 2023 ·Bioorganic & Medicinal Chemistry Letters ·Zilun Hu,Doree Sitkoff,Peter W. Glunz,(unknown),(unknown),J.K. Muckelbauer,Leonard P. Adam,Ruth R. Wexler,Mimi L. Quan	2
3	Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys 2021 ·Research and Practice in Thrombosis and Haemostasis ·Pancras C. Wong,Mimi L. Quan	6
4	Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors 2018 ·Bioorganic & Medicinal Chemistry Letters ·Zilun Hu,(unknown),Wei Han,Karen A. Rossi,Jeffrey M. Bozarth,Yiming Wu,S. Sheriff,Joseph E. Myers,Joseph M. Luettgen,Dietmar Seiffert,Ruth R. Wexler,Mimi L. Quan	16
5	Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker 2017 ·Journal of Medicinal Chemistry ·James R. Corte,Tianan Fang,(unknown),Donald Pinto,Karen A. Rossi,Joseph E. Myers,S. Sheriff,Zhen Lou,Joanna J. Zheng,Timothy W. Harper,Jeffrey M. Bozarth,Yiming Wu,Joseph M. Luettgen,Dietmar Seiffert,Carl P. Decicco,Ruth R. Wexler,Mimi L. Quan	29
6	Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency 2017 ·Bioorganic & Medicinal Chemistry Letters ·James R. Corte,Wu Yang,Tianan Fang,Yufeng Wang,(unknown),(unknown),William R. Ewing,Karen A. Rossi,Joseph E. Myers,S. Sheriff,Zhen Lou,Joanna J. Zheng,Timothy W. Harper,Jeffrey M. Bozarth,Yiming Wu,Joseph M. Luettgen,Dietmar Seiffert,Mimi L. Quan,Ruth R. Wexler,Patrick Y. S. Lam	12
7	Macrocyclic factor XIa inhibitors 2017 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),James R. Corte,Karen A. Rossi,Jeffrey M. Bozarth,Yiming Wu,S. Sheriff,Joseph E. Myers,Joseph M. Luettgen,Dietmar Seiffert,Ruth R. Wexler,Mimi L. Quan	9
8	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group 2016 ·Bioorganic & Medicinal Chemistry ·James R. Corte,Tianan Fang,Donald Pinto,Michael J. Orwat,Alan R. Rendina,Joseph M. Luettgen,Karen A. Rossi,Anzhi Wei,Vidhyashankar Ramamurthy,Joseph E. Myers,S. Sheriff,Rangaraj Narayanan,Timothy W. Harper,Joanna J. Zheng,Yixin Li,Dietmar Seiffert,Ruth R. Wexler,Mimi L. Quan	15
9	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties 2015 ·Bioorganic & Medicinal Chemistry Letters ·Donald Pinto,Joanne M. Smallheer,James R. Corte,(unknown),(unknown),Tianan Fang,Leon M. Smith,Karen A. Rossi,Alan R. Rendina,Jeffrey M. Bozarth,Ge Zhang,Anzhi Wei,Vidhyashankar Ramamurthy,S. Sheriff,Joseph E. Myers,Paul E. Morin,Joseph M. Luettgen,Dietmar Seiffert,Mimi L. Quan,Ruth R. Wexler	26
10	Pyridine and pyridinone-based factor XIa inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·James R. Corte,Tianan Fang,Jon J. Hangeland,(unknown),Alan R. Rendina,Joseph M. Luettgen,Jeffrey M. Bozarth,Frank Barbera,Karen A. Rossi,Anzhi Wei,Vidhyashankar Ramamurthy,Paul E. Morin,Dietmar Seiffert,Ruth R. Wexler,Mimi L. Quan	14
11	Abstract 9916: Potent Antithrombotic Effect of a Small-molecule, Reversible and Direct Inhibitor of Factor XIa With Minimum Bleeding Time Effect In Rabbit Models of Arterial Thrombosis and Hemostasis 2013 ·Circulation ·Pancras C. Wong,Mimi L. Quan,Carol A. Watson,Earl J. Crain,Ruth R. Wexler,Dietmar Seiffert	1
12	Phenyltriazolinones as potent factor Xa inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Mimi L. Quan,Donald Pinto,Karen A. Rossi,S. Sheriff,Richard Alexander,(unknown),Kevin Kish,Robert M. Knabb,Joseph M. Luettgen,Paul E. Morin,Angela Smallwood,Francis J. Woerner,Ruth R. Wexler	10
13	Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs 2007 ·Drug Metabolism and Disposition ·Donglu Zhang,Nirmala Raghavan,Shiang-Yuan Chen,Haiying Zhang,Mimi L. Quan,(unknown),(unknown),Patrick Y. S. Lam,Samuel J. Bonacorsi,Robert M. Knabb,Gary L. Skiles,Kan He	46
14	Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits 2007 ·Journal of Thrombosis and Thrombolysis ·Pancras C. Wong,Earl J. Crain,Carol A. Watson,Ruth R. Wexler,Patrick Y. S. Lam,Mimi L. Quan,Robert M. Knabb	28
15	Design, structure–activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey Varnes,Dean A. Wacker,(unknown),Mimi L. Quan,Christopher D. Ellis,Karen A. Rossi,(unknown),Joseph M. Luettgen,Robert M. Knabb,Steven Bai,Kan He,Patrick Y. S. Lam,Ruth R. Wexler	18
16	Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Mimi L. Quan,Qi Han,John M. Fevig,Patrick Y. S. Lam,Steve Bai,Robert M. Knabb,Joseph M. Luettgen,Pancras C. Wong,Ruth R. Wexler	16
17	Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Mimi L. Quan,Christopher D. Ellis,(unknown),Ann Y. Liauw,Patrick Y. S. Lam,Karen A. Rossi,Robert M. Knabb,Joseph M. Luettgen,Matthew Wright,Pancras C. Wong,Ruth R. Wexler	17
18	Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core 2001 ·Bioorganic & Medicinal Chemistry Letters ·John M. Fevig,Donald Pinto,Qi Han,Mimi L. Quan,James R. Pruitt,(unknown),Robert A. Galemmo,Shuaige Wang,Michael J. Orwat,Lori L. Bostrom,Robert M. Knabb,Pancras C. Wong,Patrick Y. S. Lam,Ruth R. Wexler	31
19	Balanced AT1/AT2 Receptor Antagonists. 4. XR510 and Related 5-(3-Amidopropanoyl)imidazoles Possessing Equal Affinity for the AT1 and AT2 Receptors 1995 ·Journal of Medicinal Chemistry ·Mimi L. Quan,Andrew T. Chiu,Christopher D. Ellis,Pancras C. Wong,Ruth R. Wexler,Pieter B.M.W.M. Timmermans	13
20	Pharmacology of XR510, a Potent Orally Active Nonpeptide Angiotensin II AT1 Receptor Antagonist with High Affinity for the AT2 Receptor Subtype 1995 ·Journal of Cardiovascular Pharmacology ·Pancras C. Wong,Mimi L. Quan,(unknown),(unknown),Earl J. Crain,Dale E. McCall,Carol A. Watson,(unknown),Ronald D. Smith,Ruth R. Wexler,Pieter B.M.W.M. Timmermans,Andrew T. Chiu	7

About Mimi L. Quan

Mimi L. Quan is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine, having authored 48 papers that have together received 1.4k indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (27 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (21 papers) and Atrial Fibrillation Management and Outcomes (9 papers). The work is most often cited by research in Hematology (530 citations), Internal Medicine (139 citations) and Genetics (359 citations). Mimi L. Quan has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include Ruth R. Wexler, Donald J. Cram, Pancras C. Wong, Robert M. Knabb, Joseph M. Luettgen, Dietmar Seiffert, Patrick Y. S. Lam, Christopher D. Ellis, Donald Pinto and Richard Alexander. Their work appears in journals such as Journal of the American Chemical Society, Circulation and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact